Prostate cancer: Enzalutamide is superior to bicalutamide for mCRPC.

Nature reviews. Urology

PubMedID: 26832166

Sidaway P. Prostate cancer: Enzalutamide is superior to bicalutamide for mCRPC. Nat Rev Urol. 2016;.
An abstract is not available. Please access the article through the links below.